Publications by authors named "Toshihito Tsubosaka"
Article Synopsis
- Cisplatin plus fluorouracil is commonly used to treat head and neck cancer but requires hospitalization, prompting the development of an outpatient regimen involving S-1 and nedaplatin.
- In a phase I study, 14 patients received oral S-1 for 14 days and increasing doses of intravenous nedaplatin, with the maximum tolerated dose found to be 90 mg/m², primarily causing neutropenia and thrombocytopenia.
- The recommended nedaplatin dose for further studies was established at 80 mg/m², as the new regimen showed good tolerance and a response rate of 57.1%.
Article Synopsis
- Preservation of the larynx is crucial for the quality of life in head and neck cancer treatment, specifically focusing on preserving laryngeal function through chemoradiotherapy.
- The study examined 32 patients with resectable squamous cell carcinoma, using a combination of induction chemotherapy and chemoradiotherapy, which included cisplatin, 5-fluorouracil, and weekly nedaplatin and docetaxel.
- Results showed that 21 out of 29 patients successfully preserved their laryngeal function, achieving an initial preservation rate of 93.8%, highlighting a promising approach for treating advanced laryngeal and hypopharyngeal cancer.
